1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Sector news
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
Delayed Australian Stock Exchange  -  05/20 02:10:09 am EDT
275.17 AUD   +0.43%
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
05/11Australian shares rise on healthcare, mining boost; U.S. inflation data in focus
RE
05/06Australia shares slump as inflation woes hint at more rate hikes
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Sector news Biopharmaceuticals
05/20Correction to Vir Biotechnology Shares Fall 9% Article
DJ
05/20Vir Biotechnology Shares Fall 9% After Terminating Agreement with WuXi Bio
DJ
05/20China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge
RE
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies..
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/11Hong Kong Stocks Rebound from Near Two-Month Low; Biotech Shares Rally
MT
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
CI
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
MT
05/05Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T..
CI
05/04Michel Vounatsos to Step Down as Chief Executive Officer of Biogen
CI
05/04Morgan Stanley Adjusts Biogen's Price Target to $285 from $283, Keeps Overweight Rating
MT
05/04Oppenheimer Adjusts Biogen Price Target to $225 From $240, Maintains Outperform Rating
MT
05/04RBC Raises Price Target on Biogen to $251 From $244, Maintains Outperform Rating
MT
05/04Barclays Adjusts Biogen's Price Target to $210 From $219, Keeps Equalweight Rating
MT
05/04Wedbush Trims Biogen's Price Target to $185 From $188, Citing Aduhelm Wind-Down, Mainta..
MT
05/03Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
CI
05/03Biogen's Quarterly Results Fall as Drugmaker Plans to Stop Selling Aduhelm; CEO to Step..
MT
05/03TIMELINE-Biogen CEO to leave as Alzheimer's drug struggles
RE
05/03SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
MT
05/03Biogen Q1 Non-GAAP EPS, Revenue Drop; CEO Michel Vounatsos to Leave; Reaffirms 2022 Gui..
MT
05/03TRANSCRIPT : Biogen Inc., Q1 2022 Earnings Call, May 03, 2022
CI
05/03Biogen Inc. Reaffirms Revenue Guidance for the Full Year 2022
CI
05/03Biogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm
RE
05/03Biogen quarterly profit falls 26%
RE
05/02Biogen, Scribe Therapeutics Expand Research Collaboration to Second Disease Target
MT
05/02Sage, Biogen Start Rolling Submission of New-Drug Application to US FDA for Major Depre..
MT
05/02Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application to U.S..
CI
04/28Wedbush Raises Biogen's Price Target to $188 From $185, Maintains Neutral Rating
MT
04/28Eli Lilly obesity drug data shines, shares rise
RE
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
04/28Samsung Biologics' Net Income Surges 141% in March Quarter
MT
04/27Big Biotech Firms Have Several Catalysts Lined Up, UBS Says
MT
04/27UBS Adjusts Biogen Price Target to $244 From $269, Maintains Buy Rating
MT
04/22Biogen Withdraws European Marketing Authorization Application for Alzheimer's Disease D..
MT
04/22Biogen pulls application for Alzheimer's drug in Europe
RE
04/22Biogen to withdraw Alzheimer's drug application in Europe
RE
04/22Biogen Pulls European Application for Approval of Alzheimer's Drug Aduhelm
DJ
04/21SVB Leerink Adjusts Biogen Price Target to $270 From $300, Maintains Outperform Rating
MT
04/20Samsung Biologics Co.,Ltd. completed the acquisition of the remaining 49.9% stake in Sa..
CI
04/18Wells Fargo Upgrades Biogen to Overweight From Equalweight; Adjusts Price Target to $26..
MT
04/12Barclays Adjusts Price Target for Biogen to $219 From $235, Maintains Equalweight Ratin..
MT
04/11Moody's Downgrades Biogen to Baa2 From Baa1; Outlook Negative
MT
04/08TIMELINE-Alzheimer's drug from Biogen hits Medicare coverage curbs
RE
04/08Needham Adjusts Biogen's Price Target to $262 form $290, Keeps Buy Rating
MT
04/08SECTOR UPDATE : Health Care Stocks Edge Upward Premarket Friday
MT
04/08SECTOR UPDATE : Health Care
MT
04/08Oppenheimer Adjusts Biogen's Price Target to $240 From $285, Maintains Outperform Ratin..
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on CSL LIMITED